Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02188264 · ClinicalTrials.gov registry record · Phase 1
Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
A Phase 1 study of Solid Neoplasm and Stage IVA Colorectal Cancer AJCC v7, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 10
- Study locations
NCT02188264 is a Phase 1 study of Solid Neoplasm and Stage IVA Colorectal Cancer AJCC v7 that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants, below the 940-participant average among 12 other Solid Neoplasm trials with a reported enrollment target (96% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT02188264, a Phase 1 study of Solid Neoplasm and Stage IVA Colorectal Cancer AJCC v7, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 10
- Study locations
Study Summary
This phase I/Ib trial studies the side effects and best dose of selumetinib when given together with cyclosporine in treating patients with solid tumors or colorectal cancer that have spread to other places in the body and cannot be cured or controlled with treatment. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as cyclosporine, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Giving selumetinib and cyclosporine may be a better treatment for solid tumors or colorectal cancer.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Cyclosporine
- DRUG Selumetinib
- OTHER Pharmacological Study
Study Locations (10)
Missouri
- Siteman Cancer Center at West County Hospital - Creve Coeur
- Washington University School of Medicine - St Louis
California
- University of California Davis Comprehensive Cancer Center - Sacramento
Colorado
- UCHealth University of Colorado Hospital - Aurora
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
North Carolina
- UNC Lineberger Comprehensive Cancer Center - Chapel Hill
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Pennsylvania
- University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-08-29 |
| Est. Completion | 2019-04-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02188264
The ClinicalTrials.gov registry entry for NCT02188264 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 940-participant average among 12 other Solid Neoplasm trials with a reported enrollment target (96% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02188264 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Missouri, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02188264 about?
NCT02188264 is a clinical study titled "Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer". This phase I/Ib trial studies the side effects and best dose of selumetinib when given together with cyclosporine in treating patients with solid tumors or colorectal cancer that have spread to other places in the body and cannot be cured or controlled with treatment. Selumetinib may stop the growth...
What is the current status of trial NCT02188264?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2014-08-29. Estimated completion is 2019-04-26.
What conditions does trial NCT02188264 study?
This clinical trial studies the following conditions: Solid Neoplasm, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Recurrent Colorectal Carcinoma, Stage IIIA Colorectal Cancer AJCC v7.
What interventions are being tested in trial NCT02188264?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Cyclosporine (DRUG), Selumetinib (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02188264?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02188264 being conducted?
This trial has 10 study locations across California, Colorado, Missouri, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
RECRUITING · Phase 1
-
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
COMPLETED · Phase 1
-
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.